Drugs / Ad-MAGEA3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03773744 | Feb → Oct 2020 | metastatic melanoma, skin squamous cell carcinoma | Turnstone Biologics, Corp. | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02879760 | Mar 2017 → Feb 2020 | non-small cell lung carcinoma | Turnstone Biologics, Corp. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-MAGEA3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03773744 ↗ |
| Modality | Vaccine | “Adenovirus vaccine” NCT03773744 ↗ |
| Route | Intramuscular | “Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.” NCT02879760 ↗ |